Cel-Sci: Little Known Drug Validates Multikine’s Investigation Goals
Multikine’s safety and clinical profiles have been independently verified by another proprietary formulation of cytokines for immunotherapy. IRX-2 was well tolerated in its Phase 2A clinical trial, has a well understood mechanism of action, and demonstrated a massive survival benefit. In the event of approval, Multikine would be granted 12 …
News story posted on 2020-02-06T09:47:00.0000000Z
